Reuters logo
BRIEF-IDMC Recommends Continuation Of Cytodyn's Pro 140 Pivotal Combination Therapy Trial Without Modifications
2017年12月7日 / 上午11点17分 / 7 天前

BRIEF-IDMC Recommends Continuation Of Cytodyn's Pro 140 Pivotal Combination Therapy Trial Without Modifications

Dec 7 (Reuters) - Cytodyn Inc:

* INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF CYTODYN‘S PRO 140 PIVOTAL COMBINATION THERAPY TRIAL WITHOUT MODIFICATIONS

* CYTODYN - PRO 140 PHASE 2B/3 PIVOTAL TRIAL REQUIRES 50 PATIENTS FOR COMPLETION Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below